Approved for the first line treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 2. L 858R substitution mutations.
An oral pan EGFR tyrosine kinase inhibitor.
ARCHER 1050 trial compared to either dacamitinib or gegititinib: The median progression free survival was significantly higher with dacomitinib than gefitinib 14.7 versus 9.29 months respectively, no improvement in response rate overall survival was demonstrated.
Side effects include interstitial lung disease, diarrhea, and dermatologic adverse reactions.